Solid Biosciences LLC (SLDB) — Strategic Asset Allocation Index
Solid Biosciences LLC (SLDB) has a Strategic Asset Allocation Index of 21.5% as of June 2023. Strategic assets (PP&E of $35.23 Million plus long-term investments of $-) total $35.23 Million, measured against net assets of $163.73 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Solid Biosciences LLC Strategic Asset Allocation Index (2018–2022)
This chart shows how Solid Biosciences LLC's Strategic Asset Allocation Index has evolved across 5 annual periods from 2018 to 2022. As of June 2023, the index stands at 21.5%, representing strategic assets of $35.23 Million against net assets of $163.73 Million USD. Explore SLDB cash flow metrics to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Solid Biosciences LLC (2018–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Solid Biosciences LLC from 2018 to 2022, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Solid Biosciences LLC market cap and net worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 4.6% | $9.66 Million | $9.66 Million | $- | $211.67 Million | ▲ +1.5 pp |
| 2021 | 3.1% | $6.46 Million | $6.46 Million | $- | $208.21 Million | ▼ -5.8 pp |
| 2020 | 8.9% | $11.73 Million | $11.73 Million | $- | $132.09 Million | ▼ -11.9 pp |
| 2019 | 20.8% | $16.63 Million | $16.63 Million | $- | $80.05 Million | ▲ +12.5 pp |
| 2018 | 8.3% | $10.42 Million | $10.42 Million | $- | $125.18 Million | — |